Garrett Nichols

Chief Medical Officer at Candel Therapeutics

Role: Chief Medical Officer at Candel Therapeutics
Location: Durham, NC, US
LinkedIn followers: 500 followers

Healthcare & Human ServicesView LinkedIn profile

Experience

Chief Medical Officer
Candel Therapeutics
Sep 2022 — Present
Chief Medical Officer for innovative and diversified immuno-oncology company, with late stage and early stage clinical platforms, in addition to a unique discovery platform- CAN-2409 in Ph3 clinical trials for non-metastatic prostate cancer, Ph2 for ICI-nonresponsive NSCLC, and Ph2 for borderline resectable pancreatic ductal adenocarcinoma- CAN-3110 in Ph2 clinical trial for recurrent high grade glioma- enLighten discovery platform of HSV constructs engineered to overcome the barriers of immunotherapy for cancer, including potentiating CAR-T efficacy in solid tumors

Contact information

Verified work emails, personal emails, and direct dials — unlocked in one click.

Work email
•••••@candeltx.com
Personal email
•••••@•••••.com
Direct dial
+•• ••• ••• ••••

Unlock verified contacts

Free to start · No credit card required

Current company

Candel Therapeutics

Biotechnology Research · 93 employees · Founded 1999 · Needham, Massachusetts, United States

Candel ($CADL) is a clinical stage biopharmaceutical company focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. Candel has established two clinical stage multimodal biological immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) gene constructs, respectively. CAN-3110 is the lead product candidate from the HSV platform and is currently in an ongoing investigator-sponsored phase 1 clinical trial in recurrent high-grade glioma (HGG). In addition, Candel’s enLIGHTEN™ Discovery Platform is a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. CAN-2409 is the lead product candidate from the adenovirus platform and is currently in ongoing clinical trials in non-small cell lung cancer (NSCLC) (phase 2), borderline resectable pancreatic cancer (phase 2), and localized, non-metastatic prostate cancer (phase 2 and phase 3). For more information, visit www.candeltx.com or contact us at i•••@candeltx.com.

candeltx.com

Find verified contacts for anyone on LinkedIn

Unifers gives sales teams verified emails and direct dials, enriched profiles, and outreach that lands in the inbox.

Start for free See how it works

Free plan included · No credit card required

This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.